TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03291808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Description: This 6-month intervention will include restricted calorie intake and increased physical activity. Key behavioral strategies to facilitate changes in dietary habits and activity patterns will be introduced, promoted and reinforced throughout the program. Weekly group meetings in a synchronous chat (i.e., in real time) led by a facilitator will be the venue for the group process. Extensive web-based resources to support behavior changes will be offered. Group chat sessions will meet online weekly for 6 months.
Study: NCT03878966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inserting polymer free drug eluting stent in the coronary arteries
Description: • Early invasive strategy with percutaneous coronary intervention will be done for the patients presenting with NST ACS who meet the inclusion criteria using Polymer-free drug eluting stents instead of the polymer-permanent drug eluting stents .
Study: NCT03197649

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser phototherapy treatment
Description: Laser phototherapy treatment administered in OR
Study: NCT03233646

Intervention type: DEVICE
Intervention: Retinal and Choroidal Imaging
Description: Non-invasive OCT, OCTA, and UWF fundus photography of retina

Intervention type: DEVICE
Intervention: Retinal and Choroidal Imaging
Description: Non-invasive OCT, OCTA, and UWF fundus photography of retina
Study: NCT02225301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iLook Out for Child Abuse
Description: The online learning module is an interactive, multi-media, self-paced intervention.
Study: NCT00885586

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: The needle acupuncture technique used in this trial is performed according the traditional way (TCM) using expendable needles.
Study: NCT01847066

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erbium 2940 plus cosmetics plus Impact
Description: Laser used in all arms

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erbium 2940 plus cosmetics plus Impact
Description: Laser used in all arms

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erbium 2940 plus cosmetics
Description: laser

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erbium 2940 plus cosmetics
Description: laser
Study: NCT01709422

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is the sedative drug used as an additional sedation to one of the study arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam is one of the two conventional sedative drugs included in both arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam is one of the two conventional sedative drugs included in both arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine
Description: Meperidine is one of the two conventional sedative drugs included in both arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine
Description: Meperidine is one of the two conventional sedative drugs included in both arms.
Study: NCT00877786

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Group Therapy
Description: Cognitive behavioral therapy (CBT) is a form of psychotherapy that addresses the links between thoughts, emotions and behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Group Therapy
Description: Cognitive behavioral therapy (CBT) is a form of psychotherapy that addresses the links between thoughts, emotions and behaviors.
Study: NCT00770497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 15 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for up to 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone and ramipril
Description: Pioglitazone 15 mg, tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Pioglitazone placebo-matching tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks.
Study: NCT05021302

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NOVAMAG NT-60
Description: The Electromagnetic stimulation consists of 15 sessions with 20 minutes duration and three times a week. The total length of therapy is five weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Kegel Exercises
Description: Self-supporting pelvic floor muscle strengthening exercises performed at home by contracting and relaxing quickly (2 seconds of contraction and 4 seconds of rest), followed by a slow contraction (contraction for 5 seconds, and rest for 10 seconds with five times each) five sets per day. The average length of exercise for each session is 2 minutes, with total exercise per day is 50 times. Thus, the total length of exercise is 10 minutes. It was done every day for eight weeks.
Study: NCT05771441

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neck stabilization exercise (nse)
Description: neck stabilization exercise (nse)- exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NSE + HOT PACK THERAPY
Description: NSE + HOT PACK THERAPY- exercise plus heat therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NSE + infrared therapy
Description: NSE + infrared therapy- exercise plus heat therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NSE + ultrasound therapy
Description: NSE + ultrasound therapy exercise plus heat therapy
Study: NCT03771131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-domain cognitive training
Description: Weekly sessions of multi-domain cognitive training, each lasting around one hour for an overall duration of the training of 3 months (13 sessions)
Study: NCT00737854

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: 20 patients with OLP will be selected for this study. Before this routine treatment modalities had been attempted. Removal of possible triggering drug was also considered. Local ethical committee approval will be obtained before the trial starts. Surgical procedure includes: removal of the tissue up to submucosa (containing antigenic properties that caused OLP). A specimen will be sent for histopathologic analysis. The graft sliced from healthy mucosa also up to submucosa. Then the graft trimmed on a gauze soaked in saline and adapted to recipient site. The graft was sutured in position. Checking will be done after 1 week and every two months up to 1 year. Punch biopsy will be done in 1 year after surgery for histopathologic investigations.
Study: NCT04222634

Intervention type: OTHER
Group type: OTHER
Intervention: Radiotherapy (SBRT) and/or surgery (metastasectomy)
Description: Metastasis-directed therapy (surgery and/or radiotherapy) as treatment for oligoprogressive lesions
Study: NCT01369641

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Insertion of Pressure Equalization (PE) Tubes
Description: If the subject consents to participate in the study, a separate consent for insertion of pressure equalization (PE) tubes will be obtained. The PE tubes will then be inserted into the posterior inferior quadrant of the tympanic membrane in the office under topical anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insertion of Pressure Equalization (PE) Tubes
Description: If the subject consents to participate in the study, a separate consent for insertion of pressure equalization (PE) tubes will be obtained. The PE tubes will then be inserted into the posterior inferior quadrant of the tympanic membrane in the office under topical anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate (STS)
Description: Drops of STS will be added to the experimental ear only prior to initial cisplatin infusion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline (Placebo)
Description: Drops of balanced saline solution will be added to the placebo comparator ear prior to initial cisplatin infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin chemotherapy infusion in the dose range of 80-120mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin chemotherapy infusion in the dose range of 80-120mg/m2
Study: NCT04883125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 15mg
Description: pioglitazone (7.5-30 mg) once daily plus imatinib 400 mg 6 months
Study: NCT05740163

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg product including egg white and yolk allergens
Description: Egg product either meatball or bread roll or bun including egg white and yolk allergens delivered orally in increasing dosages daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg product including egg white and yolk allergens
Description: Egg product either meatball or bread roll or bun including egg white and yolk allergens delivered orally in increasing dosages daily.
Study: NCT04330391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote dietitian supervised weight loss intervention and mobile app
Description: Please see intervention arm description for more details.
Study: NCT01529515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP3M 175 mg eq.
Description: Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP3M 263 mg eq.
Description: Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP3M 350 mg eq.
Description: Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP3M 525 mg eq.
Description: Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (20% Intralipid emulsion)
Description: Form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
Study: NCT04071262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Administered orally
Study: NCT01293630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombrabulin (AVE8062)
Description: Pharmaceutical form:solution~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Pharmaceutical form:solution~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Pharmaceutical form:solution~Route of administration: intravenous
Study: NCT02664649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Investigational Product is open label apixaban 5 mg tablets taken orally two times a day for 12 months. Subjects with 2 or more of the following characteristics will take apixaban 2.5 mg tablets orally twice daily: age ≥80 years, body weight \<60 kg, serum creatinine ≥1.5 mg/dL \[133 μMol/L\].~- Also, subjects with severe renal insufficiency \[calculated Creatinine Clearance (Cr.Cl.) (Cockroft-Gault) between 15-29 ml/min\] will take apixaban 2.5 mg tablets orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: VKA or Antiplatelet therapy
Study: NCT05440591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MetFORMIN 500 Mg Oral Tablet
Description: Metformin 500 mg tablets twice daily
Study: NCT03758274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT by Phone to Promote Treatment
Description: Structured phone intervention to identify concerns about getting alcohol use disorder treatment and to work through those concerns using cognitive behavioral principles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reading the Subject a Pamphlet on Obtaining Alcohol Use Disorder Treatment
Description: The pamphlet was created by the National Institute on Alcohol Abuse and Alcoholism to describe evidence based treatments available for alcohol use disorder and how to obtain such treatment.
Study: NCT04081168

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiotherapy
Description: Patients will undergo Stereotactic Body Radiotherapy (SBRT)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microwave Ablation
Description: Patients will undergo Microwave Ablation (MWA)
Study: NCT02753023

Intervention type: OTHER
Intervention: no intervention
Description: No intervention related

Intervention type: OTHER
Intervention: no intervention
Description: No intervention related

Intervention type: OTHER
Intervention: no intervention
Description: No intervention related

Intervention type: OTHER
Intervention: no intervention
Description: No intervention related

Intervention type: OTHER
Intervention: no intervention
Description: No intervention related

Intervention type: OTHER
Intervention: no intervention
Description: No intervention related
Study: NCT05440591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin / metFORMIN Pill
Description: Combination pill
Study: NCT02079831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy Restriction
Description: Participants will receive an intervention specifically designed for adolescents and their group assignment that relies on nutrition education, nutritional counseling, social cognitive therapy, behavioral strategies, self-monitoring, portion size reduction, and increased physical activity.~Participants will get an individualized dietary meal plan. Dietary counseling will be based on the MyPlate guidelines with extra attention and focus on appropriate protein food choice. Also in accordance to the MyPlate guidelines, all participants will be instructed to increase physical activity to 60 minutes a day as aerobic physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy Restriction
Description: Participants will receive an intervention specifically designed for adolescents and their group assignment that relies on nutrition education, nutritional counseling, social cognitive therapy, behavioral strategies, self-monitoring, portion size reduction, and increased physical activity.~Participants will get an individualized dietary meal plan. Dietary counseling will be based on the MyPlate guidelines with extra attention and focus on appropriate protein food choice. Also in accordance to the MyPlate guidelines, all participants will be instructed to increase physical activity to 60 minutes a day as aerobic physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Higher protein
Description: The higher protein group will be instructed to consume 30% of energy as protein, with 25% and 45% of energy from fat and carbohydrate, respectively.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower Protein
Description: The lower protein group will be instructed to consume 15% of energy as protein, with 25% and 60% of energy from fat and carbohydrate, respectively.
Study: NCT02753023

Intervention type: OTHER
Intervention: no intervention
Description: No intervention related
Study: NCT02534935

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rLP2086 vaccine
Description: 60 mcg or 120mcg at 0, 2 and 6 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediatric HAV vaccine
Description: 0.5-mL dose at months 0 and 6. Normal saline at month 2.
Study: NCT03912766

Intervention type: DIAGNOSTIC_TEST
Intervention: serum copeptin
Description: routine surgical method using resectoscope inserted into the urinary bladder
Study: NCT02460354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg pill dispensed once orally
Study: NCT01239381

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy-proton
Description: Dose will be determined by the size and location of the tumor(s); 2-3 treatments per week for two weeks
Study: NCT02665351

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peramivir
Description: The two regimens of Peramivir were compared

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peramivir
Description: The two regimens of Peramivir were compared
Study: NCT02220855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study: NCT02442310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone delayed release tablet formulation
Description: Deferiprone 600 mg delayed release tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone delayed release tablet formulation
Description: Deferiprone 600 mg delayed release tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone delayed release tablet formulation
Description: Deferiprone 600 mg delayed release tablet formulation
Study: NCT01949662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: 3 mg by vein one time only.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo consisting of preservative free 0.9% normal saline given one time by vein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate
Description: 8 mg/day by vein.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol decanoate
Description: 8 mg/day by vein.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete.
Study: NCT00690131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BTSCS
Description: BTSCS includes: (1) A behavioral group emphasizing motivational enhancement, skills training, education, and relapse prevention; (2) Contingency management with financial incentives to reinforce reductions in smoking; (3) Supported use of Bupropion or nicotine replacement therapy that is integrated with clients' psychiatric care in participants who are interested; and (4) Smoking cessation care coordination to increase treatment engagement and retention.
Study: NCT01539057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen
Description: The dose of fibrinogen should be calculated at 1 g of fibrinogen in order to obtain an increase in plasma fibrinogen value of 0.29 g / L to reach a final value of 2.9 g / L.~Fibrinogen ampoules powder prepared with water dilution and located in a serum at a concentration of 2g/100 ml, which will be administered by intravenous infusion for 10 minutes.~Administration before surgery starts

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: the same dose in volume of water dilution will be administered. The potential dose of fibrinogen required to obtain a final plasmatic reading of 2.9 g / L. will be computed. A serum will contain the corresponding ml of water dilution. Administered before surgery starts
Study: NCT00822250

Intervention type: OTHER
Group type: OTHER
Intervention: analysis of pigmentation
Description: cutting hair, skin description, skin biopsy for only 4 patients
Study: NCT02442310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferiprone oral solution
Description: Deferiprone 100 mg/mL oral solution
Study: NCT02526745

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the vaccine with high doses of virus content between 4.7～5.0 lgPFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the vaccine with low doses of virus content between 4.7～5.0 lgPFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the vaccine with high doses of virus content between 4.3～5.0 lgPFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the vaccine with middle doses of virus content between 4.3～5.0 lgPFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the vaccine with low doses of virus content between 4.3～5.0 lgPFU
Study: NCT03569774

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One-lung ventilation with individualized PEEP
Description: During one-lung ventilation for lung resection surgery, PEEP will be applied. After a subject's individualized PEEP (PEEP that corresponds to maximum lung compliance) is determined, the subject will receive one-lung ventilation with individualized PEEP.
Study: NCT01949662

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete.
Study: NCT02526745

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02373202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form:solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form:solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form:solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form:solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Pharmaceutical form: Tablet Route of administration: Oral